| Maio, Massimo Di |
| Recruiting | 4 | 175 | Europe | PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy | IRCCS San Raffaele | Pancreatic Ductal Adenocarcinoma | 01/22 | 01/26 | | |
| Active, not recruiting | 3 | 160 | Europe | cisplatin, etoposide | National Cancer Institute, Naples | Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Active, not recruiting | 3 | 232 | Europe | Gemcitabine, Pemetrexed, Cisplatin | National Cancer Institute, Naples | Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB | 11/24 | 11/24 | | |
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence |
|
|
| Recruiting | 2/3 | 300 | Europe | Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine | Gruppo Oncologico del Nord-Ovest | Biliary Tract Cancer, Cholangiocarcinoma | 12/28 | 01/29 | | |
NCT06341764: Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma |
|
|
| Recruiting | 2 | 38 | Europe | Durvalumab 1120 mg, Durvalumab 1500 mg, Tremelimumab i.v. at 300 mg, Cisplatin (CDDP) 25 mg/mq i.v, Gemcitabine (GEM) 1000 mg/mq i.v. | National Cancer Institute, Naples | Cholangiocarcinoma | 09/25 | 09/25 | | |
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel |
|
|
| Active, not recruiting | 2 | 49 | Europe | Atezolizumab,Paclitaxel, Carboplatin | Consorzio Oncotech | Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation | 07/24 | 07/24 | | |
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC |
|
|
| Recruiting | 2 | 16 | Europe | Cetuximab, Encorafenib | Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories | Colorectal Cancer | 08/26 | 04/27 | | |
GDFather-NEO, NCT06059547: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 30 | Europe | Nivolumab, Visugromab (CTL-002), Placebo | CatalYm GmbH | Bladder Cancer, Adult Solid Tumor | 04/25 | 04/26 | | |
NCT01593488: Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children |
|
|
| Active, not recruiting | 2 | 31 | Europe | liposomal cytarabine | National Cancer Institute, Naples, Santobono-Pausilpon Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna | Acute Lymphoblastic Leukemia | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 400 | Europe | Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib | Fondazione per la Medicina Personalizzata | Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer | 12/24 | 06/25 | | |
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy |
|
|
| Recruiting | 2 | 173 | Europe | Cetuximab, Erbitux, Avelumab, Bavencio | University of Campania "Luigi Vanvitelli" | Metastatic Colorectal Cancer | 07/25 | 07/25 | | |
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy |
|
|
| Completed | 1/2 | 31 | Europe, US | NMS-01940153E | Nerviano Medical Sciences | Unresectable Hepatocellular Carcinoma (HCC) | 01/24 | 08/24 | | |
TIR-2009-01, NCT01074684: Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer |
|
|
| Completed | N/A | 959 | Europe | | National Cancer Institute, Naples | Thyroid Cancer | 12/21 | 12/21 | | |
PROPHYBIOTA, NCT05319067: Study of Gut Microbiota Diversity in Children Aged 1-3 Years on Prolonged Antibiotic Prophylaxis for Grade 3 or Higher Vesicoureteral Reflux Compared With 2 Age-matched Control Groups |
|
|
| Recruiting | N/A | 150 | Europe | Stool sampling | Centre Hospitalier Universitaire de Nīmes | Vesicoureteral Reflux 3 | 11/26 | 11/26 | | |
FAHIC-Lung, NCT06196424: A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung). |
|
|
| Recruiting | N/A | 180 | Europe | study questionnaire to investigate family history | Fondazione Policlinico Universitario Campus Bio-Medico, A.O.U. Città della Salute e della Scienza - Molinette Hospital, IRCCS San Raffaele | Non Small Cell Lung Cancer | 08/24 | 11/24 | | |
PROFTC-I, NCT03473379: Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy |
|
|
| Recruiting | N/A | 440 | Europe | | National Cancer Institute, Naples | Cancer | 02/24 | 07/24 | | |
| Active, not recruiting | N/A | 400 | Europe | | National Cancer Institute, Naples | Ovarian Cancer | 11/24 | 11/24 | | |
PETRA, NCT02035683: PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy |
|
|
| Active, not recruiting | N/A | 220 | Europe | PET/CT | National Cancer Institute, Naples | Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB | 12/24 | 12/24 | | |
ECUN-2, NCT04584320: Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Hospitalization |
|
|
| Active, not recruiting | N/A | 40 | Europe | Stool sample | Centre Hospitalier Universitaire de Nīmes | Necrotizing Enterocolitis | 11/24 | 10/25 | | |
| Recruiting | N/A | 141 | Europe | liquid biopsy | Fondazione del Piemonte per l'Oncologia | Metastatic Colorectal Cancer | 06/21 | 06/23 | | |
| Limone, Paolo |
| Recruiting | 2 | 64 | Europe | Tocilizumab 20 Mg/mL Intravenous Solution, Actemra, MethylPREDNISolone Injectable Solution, Solumedrol | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Mauriziano Umberto I Hospital, Istituto Auxologico Italiano, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero, Universitaria Pisana | Graves Ophthalmopathy | 12/22 | 12/23 | | |
| Massaia, Massimo |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
| Walczak, Piotr |
| Active, not recruiting | 4 | 672 | Europe, Canada, US, RoW | Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C | Alimentiv Inc., Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 03/26 | 03/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Wylegala, Zbigniew |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Daperno, Marco |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
